Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Inc.

News provided by

Oct 20, 2014, 09:00 ET

NEW YORK, Oct. 20, 2014 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Repros Therapeutics, Inc. ("Repros Therapeutics" or the "Company") (NasdaqCM: RPRX -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at [email protected] or 212-697-6484.

The investigation concerns whether Retrophin and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 26, 2014, Repros Therapeutics issued a press release reporting that it had been granted a Type B Pre-NDA meeting with the FDA in the first half of November, 2014. The Company planned on seeking guidance on its planned New Drug Application (NDA) for Androxal® for the treatment of secondary hypogonadism with preservation of testicular function. Then on October 17, 2014, the Company reported that there isn't enough clinical information to hold a planned pre-investigational NDA meeting in November. Instead, the Company said it will have a "type-C" guidance meeting with the FDA next month.

On this news, shares of Repros Therapeutics fell $4.20, or 39.96%, to close at $6.31.

If you are aware of any facts relating to this investigation, or purchased shares of Repros Therapeutics, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-repros-therapeutics-inc-116349905.html

SOURCE Bronstein, Gewirtz & Grossman, LLC